- Home
- PPBT vs CLDI Comparison
PPBT vs CLDI Comparison
Compare PPBT & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPBT | CLDI |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | Israel | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PPBT | CLDI |
|---|---|---|
| Price | $1.76 | $0.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 143.1K | ★ 2.5M |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.12 |
| 52 Week High | $5.18 | $7.32 |
Technical Indicators
Market Signals| Indicator | PPBT | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 29.66 | 33.20 |
| Support Level | $0.57 | N/A |
| Resistance Level | $3.09 | $0.20 |
| Average True Range (ATR) | 0.25 | 0.01 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 22.75 | 43.63 |
Price Performance
Historical ComparisonAbout PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.